TWST Stock Analysis: Twist Bioscience | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 8.801m USD | 12M Return: 339.6% | US90184D1000 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 474M
Qual. Beats: 0
Rev. Trend: 99.6%
Qual. Beats: 4
Warnings
Tailwinds
Seasonality 7.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Twist Bioscience Corporation is a biotechnology company that manufactures and sells synthetic DNA-based products for a broad range of life science applications. Its product portfolio spans synthetic genes and gene fragments for therapeutics, diagnostics, industrial chemicals, agriculture, and academic research; oligo pools used in next-generation sequencing (NGS), CRISPR gene editing, and DNA data storage; and immunoglobulin G (IgG) proteins supporting drug discovery and development efforts. The company also offers NGS tools, including library preparation kits, exome kits, custom panels, and methylation detection kits, along with viral reference controls and respiratory research panels targeting pathogens such as SARS-CoV-2, influenza, and RSV. Additional offerings include precision DNA libraries for antibody engineering and an antibody optimization platform. Twist maintains strategic collaborations with bitBiome Inc and Lilly TuneLab, is incorporated in 2013, and is headquartered in South San Francisco, California. The company operates within the DNA synthesis (or synbio) segment of the biotechnology industry, a subfield focused on the design and large-scale manufacturing of engineered DNA sequences that serve as foundational inputs for pharmaceutical R&D, diagnostics, and emerging applications such as DNA-based data storage. Twists write DNA on silicon platform represents one of the few commercially scaled approaches in this space, which is characterized by high barriers to entry due to capital-intensive infrastructure and significant intellectual property requirements.
- Synthetic biology revenue growth accelerates across biopharma and industrial markets
- Gross margin expansion as DNA synthesis platform utilization improves
- Biopharma antibody library partnerships convert to recurring commercial orders
| Net Income: -136.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA -3.17 > 1.0 |
| NWC/Revenue: 46.56% < 20% (prev 69.76%; Δ -23.20% < -1%) |
| CFO/TA -0.08 > 3% & CFO -53.1m > Net Income -136.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.4m) vs 12m ago 2.03% < -2% |
| Gross Margin: 51.97% > 18% (prev 49.24%; Δ 2.72% > 0.5%) |
| Asset Turnover: 65.62% > 50% (prev 56.29%; Δ 9.33% > 0%) |
| Interest Coverage Ratio: -49.81 > 6 (EBIT TTM -133.2m / Interest Expense TTM 2.67m) |
| A: 0.30 (Total Current Assets 321.3m - Total Current Liabilities 120.3m) / Total Assets 672.4m |
| B: -2.13 (Retained Earnings -1.43b / Total Assets 672.4m) |
| C: -0.20 (EBIT TTM -133.2m / Avg Total Assets 658.0m) |
| D: 1.97 (Book Value of Equity 445.7m / Total Liabilities 226.7m) |
| Altman-Z'' = -4.26 = D |
| DSRI: 1.11 (Receivables 65.8m/49.9m, Revenue 431.8m/362.3m) |
| GMI: 0.95 (GM 49.24% / 51.97%) |
| AQI: 1.04 (AQ_t 0.25 / AQ_t-1 0.24) |
| SGI: 1.19 (Revenue 431.8m / 362.3m) |
| TATA: -0.12 (NI -136.7m - CFO -53.1m) / TA 672.4m) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of October 26, 2026, the stock is trading at USD 139.92 with a total of 1,857,275 shares traded. Over the past week, the price has changed by +5.40%, over one month by -11.72%, over three months by +51.36% and over the past year by +339.59%.
Current recommended Stop Loss: 112.90 (which is 19.3% or 1.9 ATR below the current price).
Twist Bioscience has received a consensus analysts rating of 4.08. Therefore, it is recommended to buy TWST.
- StrongBuy: 7
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 163.7 | 17% |
P/S = 20.3833
P/B = 23.576
Revenue TTM = 431.8m USD
EBIT TTM = -133.2m USD
EBITDA TTM = -107.8m USD
Long Term Debt = 85.0m USD (estimated: total debt 93.6m - short term 8.63m)
Short Term Debt = 8.63m USD (from shortTermDebt, last quarter)
Debt = 93.6m USD (from shortLongTermDebtTotal, last quarter) (leases 93.6m already included)
Net Debt = -73.2m USD (calculated: Debt 93.6m - CCE 166.8m)
Enterprise Value = 8.73b USD (8.80b + Debt 93.6m - CCE 166.8m)
Interest Coverage Ratio = -49.81 (Ebit TTM -133.2m / Interest Expense TTM 2.67m)
EV/FCF = -93.73x (Enterprise Value 8.73b / FCF TTM -93.1m)
FCF Yield = -1.07% (FCF TTM -93.1m / Enterprise Value 8.73b)
FCF Margin = -21.57% (FCF TTM -93.1m / Revenue TTM 431.8m)
Net Margin = -31.66% (Net Income TTM -136.7m / Revenue TTM 431.8m)
Gross Margin = 51.97% ((Revenue TTM 431.8m - Cost of Revenue TTM 207.4m) / Revenue TTM)
Gross Margin QoQ = 52.76% (prev 51.59%)
Tobins Q-Ratio = 12.98 (Enterprise Value 8.73b / Total Assets 672.4m)
Interest Expense / Debt = 2.86% (Interest Expense 2.67m / Debt 93.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -105.2m (EBIT -133.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.67 (Total Current Assets 321.3m / Total Current Liabilities 120.3m)
Debt / Equity = 0.21 (Debt 93.6m / totalStockholderEquity, last quarter 445.7m)
Debt / EBITDA = 0.68 (negative EBITDA) (Net Debt -73.2m / EBITDA -107.8m)
Debt / FCF = 0.79 (negative FCF - burning cash) (Net Debt -73.2m / FCF TTM -93.1m)
Total Stockholder Equity = 457.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.78% (Net Income -136.7m / Total Assets 672.4m)
RoE = -29.89% (Net Income TTM -136.7m / Total Stockholder Equity 457.5m)
RoCE = -24.55% (EBIT -133.2m / Capital Employed (Equity 457.5m + L.T.Debt 85.0m))
RoIC = -19.51% (negative operating profit) (NOPAT -105.2m / Invested Capital 539.2m)
WACC = 13.08% (E(8.80b)/V(8.90b) * Re(13.20%) + D(93.6m)/V(8.90b) * Rd(2.86%) * (1-Tc(0.21)))
Discount Rate = 13.20% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 96.94 | Cagr: 3.48%
[DCF] Fair Price = unknown (Cash Flow -93.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.76 | # QB: 0
Revenue Correlation: 99.63 | Revenue CAGR: 22.23% | SUE: 3.24 | # QB: 4
EPS current Quarter (2026-12-31): EPS=-0.14 | Chg30d=+12.82% | Revisions=+25% | Analysts=3
EPS current Year (2026-09-30): EPS=-1.20 | Chg30d=-24.59% | Revisions=+40% | GrowthEPS=+43.5% | GrowthRev=+21.2%
EPS next Year (2027-09-30): EPS=-0.40 | Chg30d=+46.78% | Revisions=+25% | GrowthEPS=+66.5% | GrowthRev=+20.2%
[Analyst] Revisions Ratio: +57% (up=4, down=0)